

Is unprovoked pulmonary embolism a red flag for occult malignancy?

©Karlo Gjuras¹*,

Dijana Bešić²,

lva Saraja¹,

• Marija Križanović³,

©Kristina Marić Bešić^{3,4},

©Ivana Jurin²

¹Health Centre Bjelovar-Bilogora County, Bjelovar, Croatia

²Dubrava University Hospital, Zagreb, Croatia

³University of Zagreb School of Medicine, Zagreb, Croatia

⁴University Hospital Centre Zagreb, Zagreb, Croatia **KEYWORDS:** pulmonary embolism, unprovoked, occult malignancy, venous thromboembolism, cancer risk.

CITATION: Cardiol Croat. 2025;20(9-10):252. | https://doi.org/10.15836/ccar2025.252

*ADDRESS FOR CORRESPONDENCE: Karlo Gjuras, Dom zdravlja Bjelovarsko-bilogorske županije, Preradovićeva 7, HR-43500 Daruvar, Croatia. / Phone: +385-99-6435-486 / E-mail: karlogjuras4@gmail.com

ORCID: Karlo Gjuras, https://orcid.org/0009-0006-9137-3014 • Dijana Bešić, https://orcid.org/0000-0001-9701-0253 lva Saraja, https://orcid.org/0009-0003-1341-2987 • Marija Križanović, https://orcid.org/0009-0006-6666-7694 Kristina Marić Bešić, https://orcid.org/0000-0002-4004-7271 • Ivana Jurin, https://orcid.org/0000-0002-2637-9691

Introduction: Data on the association between unprovoked pulmonary embolism (PE) and subsequent diagnosis of occult malignancy remain limited and heterogeneous. Whether an unprovoked thromboembolic event should be considered a clinical warning sign for underlying cancer is still debated.^{1,2}

Patients and Methods: We conducted a prospective observational study based on a pulmonary embolism registry from two tertiary care centers, covering the period December 2013 to December 2024. Patients with an index PE were included, while those with active cancer at baseline or a history of malignancy were excluded. Participants were classified into two groups: unprovoked PE (UPE) and non-malignancy-provoked PE (NMPE). The primary aim was to compare the incidence of newly diagnosed malignancies during follow-up between groups, with prespecified subgroup analyses according to age and sex.

Results: A total of 656 patients were enrolled (median age 73 years [IQR 60–80], 56.4% female). During a median follow-up of 3.3 years [IQR 0.9–6.3], malignancy was diagnosed in 11/193 (5.7%) in the UPE group and 19/463 (4.1%) in the NMPE group, a difference that was not statistically significant (OR 1.41, 95% CI 0.66-3.03). Age-stratified analysis revealed a significantly higher cancer incidence among patients >60 years with UPE (OR 2.41, 95% CI 1.09-5.31). This association was most pronounced in women over 60 years, where the risk of subsequent malignancy was nearly fourfold higher (OR 3.89, 95% CI 1.29-11.7).

Conclusion: In the overall population, UPE was not associated with an increased incidence of malignancy compared with NMPE. However, older women with UPE demonstrated a markedly higher risk, suggesting that this subgroup may benefit from closer clinical follow-up. Further research is warranted to confirm these observations.

RECEIVED: September 22, 2025 ACCEPTED: October 6, 2025



2. Patel SS, Tao D, McMurry HS, Shatzel JJ. Screening for occult cancer after unprovoked venous thromboembolism: Assessing the current literature and future directions. Eur J Haematol. 2023 Jan;110(1):24-31. https://doi.org/10.1111/ejh.13874